Granules India gains as its arm incorporates wholly owned subsidiary in Canada
Granules India is currently trading at Rs. 551.15, up by 5.15 points or 0.94% from its previous closing of Rs. 546.00 on the BSE.
The scrip opened at Rs. 544.65 and has touched a high and low of Rs. 555.75 and Rs. 543.00 respectively. So far 16444 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 627.45 on 03-Dec-2024 and a 52 week low of Rs. 412.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 555.75 and Rs. 530.00 respectively. The current market cap of the company is Rs. 13374.69 crore.
The promoters holding in the company stood at 38.82%, while Institutions and Non-Institutions held 32.01% and 29.17% respectively.
Granules India’s wholly owned foreign subsidiary -- M/s. Granules Pharmaceuticals, Inc., has incorporated a Wholly Owned Subsidiary, namely ‘Granules Pharmaceuticals Canada, Inc.’ in Canada on November 26, 2025.
Granules Pharmaceuticals, Inc. will hold 100% of the equity capital in Granules Pharmaceuticals Canada, Inc. It is a newly incorporated company and has not commenced its business.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
